Navigation Links
Cerulean Pharma to Present Data on CRLX101's HIF-1a Inhibition at the American Association for Cancer Research Annual Meeting
Date:4/4/2013

X101 in combination with anti-angiogenic agents are very impressive. I am excited that we can bring this combination hypothesis into the clinic, and I am encouraged by the results of this trial to date," said Dr. Keefe. "CRLX101's favorable safety profile is encouraging, and its ability to provide durable inhibition of HIF-1a could increase the benefit that anti-angiogenic agents provide to patients."

In addition, Cerulean scientists will participate in the following sessions at AACR:

  • CRLX101, a nanopharmaceutical in phase 2 clinical trials, is synergistic with antiangiogenic treatment through HIF-1a inhibition in an ovarian cancer xenograft model (April 7, 1:00 – 5:00 pm): Douglas Lazarus , director of biology at Cerulean, will present a poster on the improved efficacy of antiangiogenic drugs when combined with CRLX101.
  • Nanotechnology Approaches to the Treatment of Cancer (April 7, 1:00 – 3:00 pm): Dr. Scott D. Eliasof , vice president of research at Cerulean, will participate in a panel discussion led by Mark Davis of the California Institute of Technology on the advantages of using nanoparticles such as CRLX101 for the treatment of cancer, including how nanotechnology enabled the creation of the first clinically relevant HIF-1a inhibitor.

About CRLX101

CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1α. CRLX101 is a dynamically tumor-targeted nanopharmaceutical designed to concentrate in tumors and release its payload, camptothecin, over an extended period of time, prolonging drug exposure at the site of action. Anti-tumor activity has been observed across a wide range of cancers in animal models and in seven clinical trials. CRLX101 is currently in Phase 2 clinical development. More informatio
'/>"/>

SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cerulean Pharmas Lead Candidate Selected as a "Top 10 Oncology Project to Watch"
2. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. Valeant Pharmaceuticals Provides Update to Recent Event
5. X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies For AMD
6. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
7. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
8. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
9. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
10. Kentucky Health Cooperative To Partner With ProCare Rx For Pharmacy Benefit Management
11. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... LAS VEGAS , Jan. 23, 2015 Cord Blood ... CBAI ) ("CBAI" or the "Company")  filed a Preliminary Proxy ... ( www.sec.gov ) today, and provides an update for shareholders ... authorized shares is requested. Dear Shareholders, ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... organiser UBM Live today reported that a record 2356 unique ... an increase of 17% over 2009 attendance levels, and announced ... be held from 24-26 August, at the Transamerica Expo Center, ... took place from August 17 to 19 at La Rural ...
... Medizone International, Inc. (OTC Bulletin Board, OTCQB: ... patent application covering recent developments in its variant ... countermeasures. The application, filed under the ... countries, including all major industrialized countries for this ...
Cached Medicine Technology:UBM South America Pharma Events Attract Record Attendance 2Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection 2
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... primary lung adenocarcinoma is exceedingly rare in the ... certain lung tumors in children and adolescents. While ... lesions exist, little research has been conducted to ... malignancies in adults. Through an assessment of clinical, ...
... 1 Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer ... researchers at the University of Pittsburgh Cancer Institute (UPCI) ... findings, reported in the early online version of this ... could lead to new strategies to protect people ...
... new ways to treat aggressive brain cancers, an international ... the lowly daffodil. A new research study published in ... Journal ( http://www.fasebj.org ) offers hope that a ... be a powerful therapeutic against biologically aggressive forms of ...
... such as slipping while walking off a curb, may seem ... death in elderly individuals, according to a new study published ... Care . As the population continues to age, it is ... prepared to deal with this issue, which could significantly impact ...
... a common stomach bacterium, reduced the severity of inflammation of the ... from U-M Medical School scientists. More than half the people ... it is very unusual to find it in the United States. ... to hosting the H. pylori infection, says Peter Higgins, ...
... clear guidelines on childhood stroke after a study, published in ... variations in time lag to diagnosis, investigation and treatment. ... rehabilitation services, after a follow-up study found that 85% of ... limitations. Dr Sten Christerson studied the records ...
Cached Medicine News:Health News:Research explores lung cancer among pediatric cancer patients 2Health News:Pitt study finds NSAIDs cause stem cells to self-destruct, preventing colon cancer 2Health News:Scientists turn a new leaf to discover a compound in daffodils that targets brain cancer 2Health News:For elderly, even short falls can be deadly 2Health News:For elderly, even short falls can be deadly 3Health News:Common stomach bacteria may fight off inflammatory bowel disease caused by Salmonella 2Health News:Common stomach bacteria may fight off inflammatory bowel disease caused by Salmonella 3Health News:Childhood stroke study identifies the contraceptive pill and smoking as risk factors 2Health News:Childhood stroke study identifies the contraceptive pill and smoking as risk factors 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: